NeulandLabs is a leading manufacturer of active pharmaceutical ingredients (APIs) and a comprehensive solution provider for the pharmaceutical industry. With headquarters in Hyderabad, India, Neuland has been at the forefront of drug development and cGMP manufacturing for over three decades. The company specializes in the synthesis of library compounds, supplying NCEs and advanced intermediates throughout the clinical life-cycle, and commercial launch.

Neuland's expertise lies in manufacturing APIs and advanced intermediates from their US FDA approved facilities. They have a strong team of over 1500 employees who apply robust process chemistry in a regulatory compliant environment. Neuland is dedicated to quality, environmental health and safety, and compliance, as evidenced by their impressive track record of regulatory approvals, including 15 successful US FDA inspections.

They offer cost-effective synthesis, IP protection, and regulatory expertise, meeting customers' API needs across the full spectrum of the product lifecycle. Neuland operates a state-of-the-art R&D centre and three world-class manufacturing plants with a total reactor volume of around 907+ KL. They are certified by various regulatory bodies and have a presence in over 80 countries.

Neuland's key markets include the US and Europe, where they hold significant market share. They have filed numerous Drug Master Files (DMFs) with regulatory authorities worldwide, showcasing their commitment to global compliance and customer satisfaction. Neuland is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE)